Amitriptyline Market, By Strength (10 mg tablets, 25 mg tablets, 50 mg tablets, 75 mg tablets, 100 mg tablets, and 150 mg tablets), By Indication (Depression, Nocturnal Enuresis, Migraine, Chronic Neuropathic Pain, and Others), by Distribution Channel (Ho

Amitriptyline Market, By Strength (10 mg tablets, 25 mg tablets, 50 mg tablets, 75 mg tablets, 100 mg tablets, and 150 mg tablets), By Indication (Depression, Nocturnal Enuresis, Migraine, Chronic Neuropathic Pain, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Amitriptyline is a tricyclic antidepressant with sedative effects. Amitriptyline affects certain chemical messengers (neurotransmitters) that communicate between brain cells and help to regulate the mood. The drug is indicated for treatment of major depressive disorder, neuropathic pain, the prophylactic treatment of chronic tension type headache (CTTH) and migraine in adults, also used in the treatment of nocturnal enuresis. It is available in tablet form.
Market Dynamics
Increasing prevalence of depression or bipolar disorder is expected to drive demand for tricyclic antidepressants such as Amitriptyline, thereby contributing to growth of the global amitriptyline market. According to the Global Burden of Disease Collaborative Network, in 2017, the prevalence of bipolar disorder ranged from 0.3% to 1.2% by country, and around 46 million people suffered from the bipolar disorder worldwide. Bipolar disorder is a brain disorder, also known as manic illness, which affects the mood, energy level, and other activities.
Key features of the study:
This report provides in-depth analysis of the global amitriptyline market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global amitriptyline market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Sandoz Inc., Sun Pharmaceutical Industries Inc., Vintage Pharmaceuticals Inc., Zydus Pharmaceuticals USA Inc., Watson laboratories Inc., and Torrent Pharmaceuticals Ltd.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global amitriptyline market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurofibromatosis treatment drugs market.
Detailed Segmentation:
Global Amitriptyline Market, By Strength:
10 mg tablets
25 mg tablets
50 mg tablets
75 mg tablets
100 mg tablets
150 mg tablets
Global Amitriptyline Market, By Indication:
Depression
Nocturnal Enuresis
Migraine
Chronic Neuropathic Pain
Others
Global Amitriptyline Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Amitriptyline Market, By Region:
North America
By Strength:
10 mg tablets
25 mg tablets
50 mg tablets
75 mg tablets
100 mg tablets
150 mg tablets
By Indication:
Depression
Nocturnal Enuresis
Migraine
Chronic Neuropathic Pain
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Strength:
10 mg tablets
25 mg tablets
50 mg tablets
75 mg tablets
100 mg tablets
150 mg tablets
By Indication:
Depression
Nocturnal Enuresis
Migraine
Chronic Neuropathic Pain
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Strength:
10 mg tablets
25 mg tablets
50 mg tablets
75 mg tablets
100 mg tablets
150 mg tablets
By Indication:
Depression
Nocturnal Enuresis
Migraine
Chronic Neuropathic Pain
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Strength:
10 mg tablets
25 mg tablets
50 mg tablets
75 mg tablets
100 mg tablets
150 mg tablets
By Indication:
Depression
Nocturnal Enuresis
Migraine
Chronic Neuropathic Pain
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Strength:
10 mg tablets
25 mg tablets
50 mg tablets
75 mg tablets
100 mg tablets
150 mg tablets
By Indication:
Depression
Nocturnal Enuresis
Migraine
Chronic Neuropathic Pain
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
GCC
Israel
Rest of Middle East
Africa
By Strength:
10 mg tablets
25 mg tablets
50 mg tablets
75 mg tablets
100 mg tablets
150 mg tablets
By Indication:
Depression
Nocturnal Enuresis
Migraine
Chronic Neuropathic Pain
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Accord Healthcare Inc.*
Company Overview
Strength Portfolio
Financial Overview
Key Highlights
Market Strategies
Mylan Pharmaceuticals Inc.
Sandoz Inc.
Sun Pharmaceutical Industries Inc.
Vintage Pharmaceuticals Inc.
Zydus Pharmaceuticals USA Inc.
Watson laboratories Inc.
Torrent Pharmaceuticals Ltd.
“*” marked represents similar segmentation in other categories in the respective section.